Comparison
Dulaglutide vs. GHRP-2
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Growth
CAS no.
923950-08-7
158861-67-7
Molecular weight
59670 g/mol
817.93 g/mol
Half-life
110 h
0.5 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcD-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
4
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
1